Patents Examined by Michael C. Wilson
-
Patent number: 11974552Abstract: A mouse model that develops type 1 diabetes spontaneously and used thereof are described. In some embodiments, the mouse model expresses a combination of HLA-DQ8 and GAD65 in a C57BL/6-BTBR congenic background, where the GAD65 is expressed under the rat insulin promoter.Type: GrantFiled: August 2, 2019Date of Patent: May 7, 2024Assignee: The University of ToledoInventors: Shahnawaz Imam, Maria Alfonso-Jaume, Juan Carlos Jaume
-
Patent number: 11970706Abstract: Provided is a nonhuman animal model that is obtained by modifying a gene encoding thioredoxin and useful as a disease model of aging, kidney diseases, cardiovascular diseases, hypertension, aortic dissection, chronic obstructive lung disease, age-dependent epilepsy, abnormality of lipid metabolism, anemia, osteoporosis, abnormal immunity, etc. These variety of phenotypes are caused by the fact that a modification of a gene encoding thioredoxin induces hypofunction of thioredoxin expressed in multiple organs throughout the body. The gene encoding thioredoxin is a gene selected from among TXN, TRX, TRX1, RRDX, Txn1, Txn, Trx1 and ADF.Type: GrantFiled: December 6, 2018Date of Patent: April 30, 2024Assignees: HAMAMATSU PHOTONICS K.K.Inventors: Iori Ohmori, Mamoru Ouchida, Tomoji Mashimo
-
Patent number: 11963520Abstract: Provided are transgenic mice whose genome comprises a nucleic acid sequence encoding human cereblon (CRBN) or a fragment thereof, wherein endogenous mouse CRBN is not expressed in the transgenic mice. Also provided are cells, cell lines, tissues, and organs derivable from the transgenic mice, and methods for producing and using such mice.Type: GrantFiled: January 18, 2017Date of Patent: April 23, 2024Assignee: CELGENE CORPORATIONInventors: Rajesh Chopra, Anke Klippel
-
Patent number: 11939591Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.Type: GrantFiled: February 5, 2021Date of Patent: March 26, 2024Assignee: The Regents of the University of CaliforniaInventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
-
Patent number: 11898162Abstract: The present invention relates to methods for reprogramming a somatic cell to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.Type: GrantFiled: March 13, 2020Date of Patent: February 13, 2024Assignee: Wisconsin Alumni Research FoundationInventors: James A. Thomson, Junying Yu
-
Patent number: 11898158Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.Type: GrantFiled: April 7, 2020Date of Patent: February 13, 2024Assignee: Sangamo Therapeutics, Inc.Inventor: Edward J. Rebar
-
Patent number: 11883507Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.Type: GrantFiled: April 2, 2021Date of Patent: January 30, 2024Assignee: Friedrich Miescher Institute for Biomedical ResearchInventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
-
Patent number: 11884930Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.Type: GrantFiled: December 18, 2020Date of Patent: January 30, 2024Assignees: Sangamo Biosciences, Inc., City of HopeInventors: Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
-
Patent number: 11865166Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to Follicle Stimulating Hormone Receptor (FSHR) protein which is abundant in many ovarian cancer sub-types. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.Type: GrantFiled: August 29, 2017Date of Patent: January 9, 2024Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and BiologyInventors: David Weiner, Alfredo Perales Puchalt, Jian Yan, Anna Maria Slager
-
Patent number: 11859200Abstract: The disclosure relates to compositions, methods, and processes for the preparation, use, and/or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts for enhanced tropism to a target tissue.Type: GrantFiled: October 26, 2021Date of Patent: January 2, 2024Assignee: VOYAGER THERAPEUTICS, INC.Inventors: Mathieu E. Nonnenmacher, Jinzhao Hou, Wei Wang, Matthew Child, Shaoyong Li
-
Patent number: 11825817Abstract: In this application, the provided are: a Down syndrome rat model characterized in that a rat gene homologous to at least one gene present on a human chromosome 21 or fragment thereof is a trisomy and is transmittable to progeny; or a Down syndrome rat model characterized in that it comprises a human chromosome 21 or fragment thereof, or an exogenous rat chromosome or fragment thereof on which a rat gene homologous to the human chromosome 21 or fragment thereof is present, wherein at least one gene on the human chromosome 21 or fragment thereof or on the exogenous rat chromosome or fragment thereof is added to endogenous rat genes homologous to the at least gene so as to become a trisomy and to be transmittable to progeny: and a method for producing the Down syndrome rat model.Type: GrantFiled: September 28, 2017Date of Patent: November 28, 2023Assignees: National University Corporation Tottori University, Trans Chromosomics, Inc.Inventors: Yasuhiro Kazuki, Mitsuo Oshimura
-
Patent number: 11800858Abstract: The present invention relates to: A schizophrenia animal model wherein the model is a mouse in which an anoctamin 1 (ANO1) gene is knocked out in cholinergic neurons of a medial habenula; and a preparation method therefor and the like. The schizophrenia animal model according to the present invention targets the medial habenula which is brain tissue playing a major role in the pathogenesis of schizophrenia, and it has been confirmed that when the ANO1 gene is specifically knocked out in the cholinergic neurons of the medial habenula, positive, negative and cognitive symptoms of schizophrenia are observed, thereby confirming that schizophrenia has been induced. Therefore, the animal model of the present invention is expected to be effectively useful in schizophrenia pathogenesis research and therapeutic agent development and screening.Type: GrantFiled: July 20, 2018Date of Patent: October 31, 2023Assignee: Korea University Research and Business FoundationInventors: Jae-Yong Park, Eun Mi Hwang, Heh-In Im, Chang-Hoon Cho, Sangjoon Lee
-
Patent number: 11781156Abstract: Provided herein are methods and compositions for plakophilin-2 gene therapy for treating heart diseases such as arrhythmogenic right ventricular cardiomyopathy (ARVC) or arrhythmogenic cardiomyopathy (ACM).Type: GrantFiled: July 30, 2021Date of Patent: October 10, 2023Assignee: TENAYA THERAPEUTICS, INC.Inventors: Zhihong Jane Yang, Jaclyn Ho, Chris Reid, Jin Yang
-
Patent number: 11766033Abstract: A nonhuman animal cancer model is described. The animal model includes an animal of the genus Peromyscus and xenograft cancer cells implanted in the animal. Methods for utilizing the animal model can include evaluation of growth and development of cancer cells, as well as evaluation of known and potential cancer treatment therapies. The animal model can be utilized to examine the efficacy of an anticancer therapy at the preclinical stage, can be utilized to screen potential cancer treatments in an individualized cancer treatment protocol, and can be utilized for identification of biomarkers associated with particular cancers and/or particular anticancer therapies, among other beneficial uses.Type: GrantFiled: June 5, 2020Date of Patent: September 26, 2023Assignee: University of South CarolinaInventors: Vimala Kaza, Eleni Farmaki, Ioulia Chatzistamou, Hippokratis Kiaris
-
Patent number: 11753652Abstract: The present invention relates to one or more promoters and/or expression cassettes that can be used for enhancing expression of a heterologous gene, such as Brachury. In particular, the one or more promoters and/or expression cassettes enhance expression of heterologous genes as part of a viral vector, such as a poxvirus.Type: GrantFiled: July 28, 2016Date of Patent: September 12, 2023Assignee: Bavarian Nordic A/SInventors: Zengji Li, Alain Delcayre, Ryan Rountree
-
Patent number: 11730150Abstract: Provided are non-human animals comprising a mutation in the Fbn1 gene to model neonatal progeroid syndrome with congenital lipodystrophy (NPSCL). Also provided are methods of making such non-human animal models. The non-human animal models can be used for screening compounds for activity in inhibiting or reducing NPSCL or ameliorating NPSCL-like symptoms or screening compounds for activity potentially harmful in promoting or exacerbating NPSCL as well as to provide insights in to the mechanism of NPSCL and potentially new therapeutic and diagnostic targets.Type: GrantFiled: December 17, 2019Date of Patent: August 22, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Charleen Hunt, Jason Mastaitis, Guochun Gong, Ka-Man Venus Lai, Jesper Gromada, Aris N. Economides
-
Patent number: 11723348Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD47, and methods of use thereof.Type: GrantFiled: November 2, 2020Date of Patent: August 15, 2023Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.Inventors: Yuelei Shen, Yang Bai, Jian Ni, Rui Huang, Chengzhang Shang, Yanan Guo
-
Patent number: 11673928Abstract: Described herein is a method for producing a chimeric non-human animal expressing a human ETV2 gene comprising: a) generating an ETV2 null non-human animal cell, wherein both copies of the non-human ETV2 gene carry a mutation that prevents production of functional ETV2 protein in said non-human animal; b) creating an ETV2 null non-human blastocyst by somatic cell nuclear transfer comprising fusing a nucleus from said ETV2 null non-human animal cell of a) into an enucleated non-human oocyte and activating said oocyte to divide so as to form an ETV2 null non-human blastocyst; c) introducing human stem cells into the ETV2 null non-human blastocyst of b); and d) implanting said blastocyst from c) into a pseudopregnant surrogate non-human animal to generate a chimeric non-human animal expressing human ETV2.Type: GrantFiled: March 3, 2016Date of Patent: June 13, 2023Assignee: Regents of the University of MinnesotaInventors: Daniel J. Garry, Mary G. Garry, Tara Rasmussen, Naoko Koyano
-
Patent number: 11653636Abstract: The present invention relates to a Pde6b-deficient animal model of retinal degeneration produced by engineered endonucleases, and a method for producing the same. In the animal model of retinal degeneration according to the present invention, only a specific target gene can be removed using engineered endonucleases, so that mutagenesis can be stably achieved. In addition, it is possible to produce a congenital animal model through genetic manipulation at the embryonic stage rather than through acquired factors, which allows for production of an animal model that uniformly exhibits symptoms of the disease in question without being influenced by other factors.Type: GrantFiled: November 15, 2019Date of Patent: May 23, 2023Assignees: UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, THE ASAN FOUNDATIONInventors: Joo Yong Lee, In Jeoung Baek, Young Hoon Sung
-
Patent number: 11647737Abstract: Provided is a genetically modified non-human mammal that comprises an anchor DNA sequence inserted at an endogenous locus of a secretory milk protein gene, wherein the anchor DNA sequence comprises a site-specific recombinase recognition site. Also provided is a genetically modified non-human mammal that comprises a transgene inserted at an endogenous locus of a secretory milk protein gene, wherein the transgene encodes a secretory protein and is operably linked to the endogenous promoter of said secretory milk protein gene, and wherein the transgene is flanked by a pair of site-specific recombinase resulting sites. The genetically modified non-human mammals provided can be used for producing the secreted recombinant protein encoded by the transgene from the milk produced by the genetically modified non-human mammals.Type: GrantFiled: December 29, 2017Date of Patent: May 16, 2023Assignees: ASC THERAPEUTICS INC., THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Ruby Yanru Tsai, Jie Xu, Yuqing Chen, Jifeng Zhang, Ling-Jie Kong